Replies to post #82828 on Biotech Values

[DewDiligence]

IDIX Major Shareholders

[Updated for NVS Form-4/A filing on 9/1/09, which corrected a minor
clerical error in NVS’ “true up” purchase on 8/21/09. The denominator
used to calculate the percentages shown below is 66.3M, the number of
basic shares outstanding, which is less than the 71M figure I use
for valuation purposes (#msg-40353178).]

 
                    Shares   Stake 
 Novartis         31,320,964 47.2% 
 MPM Capital       3,321,534  5.0% 
 GlaxoSmithKline   2,474,527  3.7% 
 JP Sommadossi*    2,219,754 *3.3% 
  
 *JP Sommadossi, IDIX’s CEO, owns 1.8M options 
 in addition to the 2.2M shares shown in the table.